Similar articles

• Ticlopidine: quo vadis? Subarachnoid hemorrhage.

  Ono H, Mizukami M, Kitamura K, Kikuchi H. Ono H, et al. Agents Actions Suppl. 1984;15:259-72. Agents Actions Suppl. 1984. PMID: 6385650 Clinical Trial. No abstract available.
• Clinical and biological double-blind-study of ticlopidine in preventive treatment of sickle-cell disease crises.

  Cabannes R, Lonsdorfer J, Castaigne JP, Ondo A, Plassard A, Zohoun I. Cabannes R, et al. Agents Actions Suppl. 1984;15:199-212. Agents Actions Suppl. 1984. PMID: 6385647 Clinical Trial. No abstract available.
• Evaluation of the antithrombotic efficacy of ticlopidine in man.

  Panak E, Blanchard J, Roe RL. Panak E, et al. Agents Actions Suppl. 1984;15:148-66. Agents Actions Suppl. 1984. PMID: 6385644 Clinical Trial. No abstract available.
• [Preventive treatment of cerebrovascular accidents of arterial origin].

  Castillo V, Bogousslavsky J, Vuadens P. Castillo V, et al. Praxis (Bern 1994). 1996 Feb 6;85(6):159-63. Praxis (Bern 1994). 1996. PMID: 8701178 Review. French.
• Drug therapy of neurovascular disease.

  Weinberger J, Frishman WH, Terashita D. Weinberger J, et al. Cardiol Rev. 2003 May-Jun;11(3):122-46. doi: 10.1097/01.CRD.0000053459.09918.92. Cardiol Rev. 2003. PMID: 12705843 Review.